Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2023-12-27 00:00:00 ET · period of report 2023-12-22 · accession 0001209191-23-059816 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-12-27 | 2023-12-22+ | ELVN | Patel Anish | COO | S - Sale | $15.03 | -1,085 | 35.6K | -3% | -$16.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-22 | S | D | 983 | $15.03 | 35,739 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $15.00 to $15.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Common Stock | 2023-12-26 | S | D | 102 | $15.01 | 35,637 | D | — | — |